While both BRCA1 and BRCA2 mutations have been extensively studied relative to pancreatic cancer risk, these screening studies have also demonstrated a higher prevalence of IPMNs in patients with BRCA mutations. This evidence concerns the gene BRCA2 and pancreatic neoplasm.